Clinical Trial Update: Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions [Phase 1]

View source ↗

Summary

Phase Ib study of Radium-223 dichloride in combination with Paclitaxel for cancers with bone lesions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Neoplasms, Bone Diseases | Phase 1 | Status: COMPLETED